We’ve all heard about the most common allergies – house dust mite, peanut, pollen, cow’s milk protein, hen’s egg, shellfish and more. DBV-Technologies’ website at www.dbv-technologies.com/en is dedicated to a new method of diagnosing and treating several of these allergies, and the company has recently begun to look at using this new technology to treat other conditions, such as Eosinophilic Esophagitis, an allergic inflammatory condition.
Treating allergies has always been difficult. Injections and oral drops have not always proven to be very effective and may be hard to administer to children. More seriously, the cure has sometimes proven to be worse than the disease, in the case of treatments actually causing full-blooded anaphylactic shock. The Langerhans cells, pictured in the image below, hold the key to a safer way of treating allergies. These are some of the body’s most tolerogenic cells, making them ideal recipients of the antigens sprayed on the back of every Viaskin patch, DBV-Technologies’ cutting-edge epicutaneous allergy technology. The ‘Viaskin technology’ section of the company website provides more detail on how this approach works.